Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2018 02:41 ET | Source: H. Lundbeck A/S

Dr. Deborah Dunsire bliver ny administrerende direktør for Lundbeck

Valby, Denmark, 2. juli 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at bestyrelsen har udnævnt Dr. Deborah Dunsire som ny administrerende direktør for Lundbeck. Dr. Deborah Dunsire...
June 08, 2018 11:24 ET | Source: H. Lundbeck A/S

Positive kliniske fase III-resultater med vortioxetin i japanske patienter med svær depression (MDD)

Nye kliniske fase III-data fra et studie udført i Japan, påviser effekt af vortioxetin i forhold til placebo ved behandling af MDD hos voksne japanske patienter De positive resultater indikerer, at...
June 08, 2018 11:24 ET | Source: H. Lundbeck A/S

Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder

New clinical phase III data from a study conducted in Japan demonstrate the efficacy of vortioxetine compared to placebo for the treatment of Major Depressive Disorder (MDD) in Japanese...
June 06, 2018 14:56 ET | Source: H. Lundbeck A/S

Lundbeck og det amerikanske Justitsministerium (Department of Justice) er blevet enige om hovedpunkterne for en aftale

Valby, Danmark, 6. juni 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort, at selskabets amerikanske datterselskab, Lundbeck LLC, har indgået en aftale med det amerikanske Justitsministerium...
June 06, 2018 14:56 ET | Source: H. Lundbeck A/S

Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice

Valby, Denmark, 6 June 2018 - H. Lundbeck A/S (Lundbeck) today announced that its U.S. subsidiary Lundbeck LLC has reached an agreement in principle to resolve the U.S. Department of Justice (DOJ)...
June 01, 2018 08:53 ET | Source: H. Lundbeck A/S

Lundbecks og Otsukas Rxulti® (brexpiprazol) får positiv udtalelse vedrørende godkendelse i EU

Pressemeddelelse Valby den 1. juni 2018 En endelig afgørelse fra EU Kommissionen ventes i løbet af 67 dage. H. Lundbeck A/S (Lundbeck) og Otsuka...
June 01, 2018 08:53 ET | Source: H. Lundbeck A/S

Lundbeck and Otsuka’s Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults

Press release Valby, 1 June 2018 A final decision from the European Commission is expected within 67 days. H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce...
May 23, 2018 05:22 ET | Source: H. Lundbeck A/S

Kapitalforhøjelse i Lundbeck med 41.946 aktier (0,0211 % af udestående aktier) som følge af warrant-program for medarbejdere

Valby, Danmark, 23. maj 2018 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK 209.730 som følge af udnyttelsen af medarbejder-warrants. ...
May 23, 2018 05:22 ET | Source: H. Lundbeck A/S

Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 23 May 2018 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 209,730 as a consequence of the exercise of employee warrants. The...
May 08, 2018 01:42 ET | Source: H. Lundbeck A/S

Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS

HIGHLIGHTS Revenue reached DKK 4,585 million in the first quarter of 2018 representing an increase of 9% (14% in local currencies) compared to the same period in 2017 Revenue of Abilify...